Clinical Trial Update: A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV [Phase 1]

View source ↗

Summary

An update on a Phase 1 trial evaluating JCXH-108, an mRNA-based vaccine for respiratory syncytial virus (RSV) infection, developed by Immorna Biotherapeutics. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• JCXH-108

Snippet

Sponsor: Immorna Biotherapeutics, Inc. | Conditions: Respiratory Syncytial Virus (RSV), Infectious Disease | Phase 1 | Status: ACTIVE_NOT_RECRUITING